One-year timeline kinetics of cytokine-mediated cellular immunity in dogs vaccinated against visceral leishmaniasis

BMC Veterinary Research

Márcio S S Araújo²  Olindo A Martins-Filho²  Rodolfo C Giunchetti¹  Kelvinson F Viana¹  Ludmila M Cardoso²  Michelle H França-Dias²  Vitor M Ribeiro³  Bruno H Marteleto²  Rodrigo P Soares²  Marcela L Moreira²  Christiane Costa-Pereira² 

[1]Laboratório de Biologia das Interações Celulares, Departamento de Morfologia, Universidade Federal de Minas Gerais, Av. Antônio Carlos, 6627, Belo Horizonte, 31270-901, MG, Brazil

[2]Laboratório de Biomarcadores de Diagnóstico e Monitoração, Centro de Pesquisas René Rachou/FIOCRUZ – MG, Av. Augusto de Lima, 1715, Belo Horizonte, 30190-002, MG, Brazil

[3]Clínica Veterinária Santo Agostinho, Avenida Amazonas, 2218, Belo Horizonte, 30180-00, MG, Brazil

关键词: Cytokines;    Leishmune®;    Vaccine;    Canine visceral leishmaniasis;   

Others  :  1175034
DOI  :  10.1186/s12917-015-0397-6

 received in 2014-12-03, accepted in 2015-03-17,  发布年份 2015

【 摘 要 】

Background

The main control strategy for visceral leishmaniasis in Brazil has been based on the elimination of seropositive dogs, although this is not widely accepted. In this context, the use of a long-lasting protective vaccine against canine visceral leishmaniasis (CVL) has been highly expected. The aim of this work was to determine the timeline kinetics of the cytokine microenvironment derived from circulating leukocytes as supportive immunological biomarkers triggered by Leishmune® vaccine. Cross-sectional kinetic analysis of cellular immunity cytokines was carried out at three times (1, 6 and 12 months) after primovaccination with Leishmune®. In vitro short-term whole blood cultures were stimulated with Leishmania infantum soluble antigen (SLAg). The secreted cytokine signatures and their major sources were determined.

Results

At six months after vaccination, Leishmune® induced an increase in IL-8, IFN-γ, IL-17a and TNF-α levels and a decrease in IL-10. Cytokine signature analysis revealed a shift in the microenvironment towards a pro-inflammatory profile mediated by IL-8 and IFN-γ. Both, CD4⁺ (↑TNF-α⁺ and ↑IFN-γ ⁺) and CD8⁺ (↑IL-17a and ↓IL-4) T-cells contributed to the acquired immune responses observed after stimulation with SLAg.

Conclusions

The changes observed in the cytokine profile suggested that Leishmune® was able to induce an effective response at six months after primovaccination. After one year, it returned to baseline suggesting the need of additional boosting.

【 授权许可】

   
2015 Costa-Pereira et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]WHO: Control of the Leishmaniases: report of a meeting of the WHO Expert Committee on the Control of Leishmaniases, Geneva, 22-26 March 2010. World Health Organization WHO Tech Rep Ser 2010, 949:1-186.
• [2]Desjeux P: Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 2004, 27:305-18.
• [3]Dantas-Torres F: The role of dogs as reservoirs of Leishmania parasites, with emphasis on Leishmania (Leishmania) infantum and Leishmania (Viannia) braziliensis. Vet Parasitol 2007, 149:139-46.
• [4]Maia-Elkhoury AN, Alves WA, Sousa-Gomes ML, Sena JM, Luna EA: Visceral leishmaniasis in Brazil: trends and challenges. Cad Saude Publica 2008, 24:2941-7.
• [5]Baneth G, Shaw SE: Chemotherapy of canine leishmaniosis. Vet Parasitol 2002, 106:315-24.
• [6]Quinnell RJ, Courtenay O: Transmission, reservoir host and control of zoonotic visceral leishmaniasis. Parasitology 2009, 136:1915-34.
• [7]Gramiccia M, Gradoni L: The current status of zoonotic leishmaniases and approaches to disease control. Int J Parasitol 2005, 35:1169-80.
• [8]Bongiorno G, Paparcone R, Foglia Manzillo V, Oliva G, Cuisinier AM, Gradoni L: Vaccination with LiESP/QA-21 (CaniLeish®) reduces the intensity of infection in Phlebotomusperniciosus fed on Leishmania infantum infected dogs a preliminary xenodiagnosis study. Vet Parasitol 2013, 197:691-5.
• [9]Moreno J, Alvar J: Canine leishmaniasis: epidemiological risk and the experimental model. Trends Parasitol 2002, 18:399-405.
• [10]Gazzinelli RT, Ropert C, Campos MA: Role of the Toll/interleukin-1 receptor signaling pathway in host resistance and pathogenesis during infection with protozoan parasites. Immunol Rev 2004, 201:9-25.
• [11]Carrillo E, Moreno J: Cytokine profiles in canine visceral leishmaniasis. Vet Immunol Immunopathol 2009, 128:67-70.
• [12]Barbiéri CL: Immunology of canine leishmaniasis. Parasite Immunol 2006, 28:329-37.
• [13]Alvar J: Canine leishmaniasis. Adv Parasitol 2004, 57:1-88.
• [14]Reis AB, Teixeira-Carvalho A, Giunchetti RC, Guerra LL, Carvalho MG, Mayrink W, et al.: Phenotypic features of circulating leucocytes as immunological markers for clinical status and bone marrow parasite density in dogs naturally infected by Leishmania chagasi. Clin Exp Immunol 2006, 146:303-11.
• [15]Lemesre JL, Holzmuller P, Cavaleyra M, Goncalves RB, Hottin G, Papierok G: Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes. Vaccine 2005, 23:2825-40.
• [16]Palatnik-de-Sousa CB: Vaccines for leishmaniasis in the fore coming 25 years. Vaccine 2008, 26:1709-24.
• [17]Nagill R, Kaur S: Vaccine candidates for leishmaniasis: a review. Int Immunopharmacol 2011, 11:1464-88.
• [18]da Silva VO, Borja-Cabrera GP, Correia Pontes NN, de Souza EP, Luz KG, Palatnik M, et al.: A phase III trial of efficacy of the FML-vaccine against canine kalaazar in an endemic area of Brazil (Sao Goncalo do Amaranto, RN). Vaccine 2000, 19:1082-92.
• [19]Borja-Cabrera GP, Correia Pontes NN, da Silva VO, ParaguaideSouza E, Santos WR, Gomes EM, et al.: Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (Sao Goncalo do Amarante, RN). Vaccine 2002, 20:3277-84.
• [20]Borja-Cabrera GP, Santos FN, Bauer FS, Parra LE, Menz I, Morgado AA, et al.: Immunogenicity assay of the Leishmune vaccine against canine visceral leishmaniasis in Brazil. Vaccine 2008, 26:4991-7.
• [21]Fernandes AP, Costa MM, Coelho EA, Michalick MS, de Freitas E, Melo MN, et al.: Protective immunity against challenge with Leishmania (Leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein. Vaccine 2008, 29:5888-95.
• [22]Araujo MS, de Andrade RA, Sathler-Avelar R, Teixeira-Carvalho A, Andrade MC, Vianna LR, et al.: T-cell-derived cytokines, nitric oxide production by peripheral blood monocytes and seric anti-Leishmania (Leishmania) chagasi IgG subclass patterns following immunization against canine visceral leishmaniasis using Leishvaccine and Leishmune. Vaccine 2009, 27:1008-17.
• [23]Silva ML, Martins MA, Espírito-Santo LR, Campi-Azevedo AC, Silveira-Lemos D, Ribeiro JG, et al.: Characterization of main cytokine sources from the innate and adaptive immune responses following primary 17DD yellow fever vaccination in adults. Vaccine 2011, 29:583-92.
• [24]Estrela-Lima A, Araújo MSS, Soares RP, Ribeiro LGR, Damasceno KA, Costa AT, et al. Plasma Biomarkers Profile of female dogs with mammary carcinoma and its association with clinical and pathological features. Vet Comp Oncology. 2014. (in press).
• [25]Chamizo C, Moreno J, Alvar J: Semi-quantitative analysis of cytokine expression in asymptomatic canine leishmaniasis. Vet Immunol Immunopathol 2005, 103:67-75.
• [26]Reis AB, Giunchetti RC, Carrillo E, Martins-Filho AO, Moreno J: Immunity to Leishmania and the rational search for vaccines against canine leishmaniasis. Trends Parasitol 2010, 26:341-9.
• [27]Araujo MS, Andrade RA, Satheler-Avelar R, Magalhaes CP, Carvalho AT, Andrade MC, et al.: Immunological changes in canine peripheral blood leukocytes triggered by immunization with first or second generation vaccines against canine visceral leishmaniasis. Vet Immunol Immunophathol 2011, 141:64-75.
• [28]Murray YHW, Lu CM, Mauzes , Freeman NS, Moreira AL, Kaplan G, et al.: Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. Infect Immun 2002, 70:6284-93.
• [29]Vouldoukis I, Drapier JC, Nüssler AK, Tselentis Y, Da Silva OA, Gentilini M, et al.: Canine visceral leishmaniasis: successful chemotherapy induces macrophage antileishmanial activity via the L-arginine nitric oxide pathway. Antimicrob Agents Chemother 1996, 40:253-6.
• [30]Pinelli E, Gebhard D, Mommaas AM, van Hoeij M, Langermans JA, Ruitenberg EJ, et al.: Infection of a canine macrophage cell line with leishmania infantum: determination of nitric oxide production and anti-leishmanial activity. Vet Parasitol 2000, 92:181-9.
• [31]Kemp K, Kemp M, Kharazmi A, Kurtzhals JAL, Theander TG: Leishmania-specific T cells expressing interferon-gamma (IFN-γ) and IL-10 upon activation are expanded in individuals cured of visceral leishmaniasis. Clin Exp Immunol 1999, 116:500-4.
• [32]Pinelli E, Ellick-Kendrick R, Wagenaar J, Bernadina W, Real G, Ruitenberg J: Cellular and humoral immune responses in dogs experimentally and naturally infected with Leishmania infantum. Infec Immun 1994, 62:229-35.
• [33]Alves CF, de Amorim IF, Moura EP, Ribeiro RR, Michalick MS, Kalapothakis E, et al.: Expression of IFN-gamma, TNF-alpha, IL-10 and TGF-beta in lymph nodes associates with parasite load and clinical form of disease in dogs naturally infected with Leishmania (Leishmania) chagasi. Vet Immunol Immunopathol 2009, 128:349-58.
• [34]Holzmuller P, Cavaleyra M, Moreaux J, Kovacic R, Vincendeau P, Papierok G, et al.: Lymphocytes of dogs immunised with purified excreted-secreted antigens of Leishmania infantum co-incubated with Leishmania infected macrophages produce IFN gamma resulting in nitric oxide-mediated amastigote apoptosis. Vet Immunol Immunopathol 2005, 106:247-57.
• [35]Lemesre JL, Holzmuller P, Gonçalves RB, Bourdoiseau G, Hugnet C, Cavaleyra M, et al.: Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial. Vaccine 2007, 21:4223-34.